BACKGROUND: Xenoreactive human natural antibodies (NAb) are predominantly directed against galactose-alpha(1,3)galactose (Gal). Binding of immunoglobulin (Ig) G and IgM NAb activates porcine endothelial cells (pEC) and triggers complement lysis responsible for hyperacute xenograft rejection. In vitro, IgG NAb induce human natural killer (NK) cell-mediated lysis of pEC by antibody-dependent cell-mediated cytotoxicity (ADCC). The present study examined the levels of anti-porcine NAb in a large number of individuals and addressed the functional role of non-Gal anti-porcine NAb. METHODS: Sera from 120 healthy human blood donors were analyzed for the presence of anti-porcine NAb by flow cytometry using porcine red blood cells (pRBC), lymphoblastoid cells (pLCL), and pEC derived from control or Gal-deficient pigs. Xenogeneic complement lysis was measured by flow cytometry using human serum and rabbit complement. ADCC was analyzed by chromium-release assays using human serum and freshly isolated NK cells. RESULTS: Human IgM binding to pRBC was found in 93% and IgG binding in 86% of all samples. Non-Gal NAb comprised 13% of total IgM and 36% of total IgG binding to pEC. NAb/complement-induced lysis and ADCC of Gal-deficient compared to Gal-positive pEC were 21% and 29%, respectively. The majority of anti-Gal and non-Gal IgG NAb were of the IgG2 subclass. CONCLUSIONS: The generation of Gal-deficient pigs has overcome hyperacute anti-Gal-mediated xenograft rejection in nonhuman primates. Non-Gal anti-porcine NAb represent a potentially relevant immunological hurdle in a subgroup of individuals by inducing endothelial damage in xenografts.
BACKGROUND: Xenoreactive human natural antibodies (NAb) are predominantly directed against galactose-alpha(1,3)galactose (Gal). Binding of immunoglobulin (Ig) G and IgM NAb activates porcine endothelial cells (pEC) and triggers complement lysis responsible for hyperacute xenograft rejection. In vitro, IgG NAb induce human natural killer (NK) cell-mediated lysis of pEC by antibody-dependent cell-mediated cytotoxicity (ADCC). The present study examined the levels of anti-porcine NAb in a large number of individuals and addressed the functional role of non-Gal anti-porcine NAb. METHODS: Sera from 120 healthy human blood donors were analyzed for the presence of anti-porcine NAb by flow cytometry using porcine red blood cells (pRBC), lymphoblastoid cells (pLCL), and pEC derived from control or Gal-deficientpigs. Xenogeneic complement lysis was measured by flow cytometry using human serum and rabbit complement. ADCC was analyzed by chromium-release assays using human serum and freshly isolated NK cells. RESULTS:Human IgM binding to pRBC was found in 93% and IgG binding in 86% of all samples. Non-GalNAb comprised 13% of total IgM and 36% of total IgG binding to pEC. NAb/complement-induced lysis and ADCC of Gal-deficient compared to Gal-positive pEC were 21% and 29%, respectively. The majority of anti-Gal and non-Gal IgG NAb were of the IgG2 subclass. CONCLUSIONS: The generation of Gal-deficientpigs has overcome hyperacute anti-Gal-mediated xenograft rejection in nonhuman primates. Non-Gal anti-porcine NAb represent a potentially relevant immunological hurdle in a subgroup of individuals by inducing endothelial damage in xenografts.
Authors: Hidetaka Hara; Andrew Bentall; Cassandra Long; Jason Fang; Oleg Andreyev; John Lunz; Mohamed Ezzelarab; Kareem M Abu-Elmagd; Ron Shapiro; David Ayares; Mark Stegall; David K C Cooper Journal: Xenotransplantation Date: 2013-09-03 Impact factor: 3.907
Authors: Kim M Wigglesworth; Waldemar J Racki; Rabinarayan Mishra; Eva Szomolanyi-Tsuda; Dale L Greiner; Uri Galili Journal: J Immunol Date: 2011-02-25 Impact factor: 5.422
Authors: Laura Higginbotham; Dave Mathews; Cynthia A Breeden; Mingqing Song; Alton Brad Farris; Christian P Larsen; Mandy L Ford; Andrew J Lutz; Matthew Tector; Kenneth A Newell; A Joseph Tector; Andrew B Adams Journal: Xenotransplantation Date: 2015-04-03 Impact factor: 3.907
Authors: Eefje M Dons; Claudia Montoya; Cassandra E Long; Hidetaka Hara; Gabriel J Echeverri; Burcin Ekser; Corin Ezzelarab; Dasha Roa Medellin; Dirk J van der Windt; Noriko Murase; Lora H Rigatti; Robert Wagner; Roman F Wolf; Mohamed Ezzelarab; Lori J West; Jan N M Ijzermans; David K C Cooper Journal: Transplantation Date: 2012-04-27 Impact factor: 4.939
Authors: Agnes M Azimzadeh; Guerard W Byrne; Mohamed Ezzelarab; Emily Welty; Gheorghe Braileanu; Xiangfei Cheng; Simon C Robson; Christopher G A McGregor; David K C Cooper; Richard N Pierson Journal: Xenotransplantation Date: 2014-09-01 Impact factor: 3.907